| Scientific program – 03.12.2026

Thursday, December 3

from 08.00	Door opening Networking Area	Networking Area
08.30–08.45	**Opening & Welcome Address of the 58th Annual Meeting of the Swiss Society of Nephrology**	**Room Aare**
08.45–09.30	**State of the Art Lecture 1:** The Art of Thinking Clearly **Dr. Rolf Dobelli, Luzern**	**Room Aare**
09.30–11.00	**Short Oral Session 1**	**Room Aare**
09.32 / SO-30 Basic Science	Structure and function analysis of (likely) pathogenic NPHS2 missense variants in cell culture and zebrafish	* Blanda Beci, Zürich
09.37 / SO-10 Basic Science	Establishing imaging mass cytometry for high-dimensional translational research in nephrology	Cyril Carvalho, Basel
09.42 / SO-32 Basic Science	Two methods for histomorphometry of aortic microcalcifications in experimental kidney disease using in-situ binding of exogenous Fetuin-A	* Miguel Correia, Bern
09.47 / SO-19 Basic Science	Less pain, same answers? Diagnostic agreement and patient experience with capillary versus venous blood sampling in children	* Lara-Julie Hess, Basel
09.52 / SO-03 Basic Science	A sex-stratified pilot study on renal osteodystrophy and antiresorptive effects in the BXD consortium of recombinant inbred mice	* Yunsu Jang, Bern
09.57 / SO-35 Basic Science	Variation in CKD-induced aortic calcification across five inbred mouse strains	* Sandra Stefanikova, Bern
10.02 / SO-05 Transplantation	Association of HLA-B leader constellation with BK polyomavirus and cytomegalovirus infections in renal allograft recipients	* Leonie Ballmer, Basel
10.07 / SO-18 Transplantation	Kidney Allograft Proteomics Reveals Shared Inflammatory and Distinct T Cell– and Antibody-Mediated Rejection Signatures	Matthieu Halfon, Fribourg

* = YSN submission

Thursday, December 3

10.12 / SO-16 Transplantation	Incidence of human papillomavirus-related cancers in solid organ transplant recipients: a retrospective cohort study in Geneva	* Nathalie Hammer, Genève
10.17 / SO-14 Transplantation	Immune cell identification in a routinely-processed kidney allograft biopsy using imaging mass cytometry	Marine Nachit, Basel
10.23 / SO-13 Transplantation	Grafalon versus Thymoglobulin in Kidney Transplantation: A Retrospective Single-Center Cohort Study of Efficacy, Safety, and Graft Outcomes	* Pabithra Pushparasa, Basel
10.28 / SO-02 Transplantation	A novel clinical prediction model to support kidney transplant decision-making	Simon Schwab, Bern
10.33 / SO-07 Transplantation	Belatacept Conversion in Simultaneous Pancreas-Kidney and Liver-Kidney Transplant Recipients: A Single-Center Cohort and Literature Synthesis	* Lukas Weidmann, Zürich
10.38 / SO-21 Transplantation	Mechanisms and signatures of immune tolerance following combined kidney and hematopoietic stem cell transplantation	* Yves Zurbuchen-Ferrari, Zürich
10.43 / SO-01 Transplantation	Successful treatment of refractory GAVE with bevacizumab enabling kidney transplantation	Nina Weber, Zürich
10.48 / SO-06 RRT	ATTEND-NN: Language Barriers and Appointment Burden Are Associated with Non-attendance at Non-nephrology Clinics in Patients Receiving Dialysis	Nina Weber, Zürich
10.53 / SO-31 RRT	Temporal trends in characteristics and outcomes of patients initiating dialysis in Switzerland from 2014 to 2025	Rebecca Guidotti, Zürich
10.58 / SO-27 RRT	Prevalence and Determinants of Hypothyroidism in Patients on Routine Hemodialysis in Somalia.	Mohamed Siyad, Mogadishu (SOM)

* = YSN submission

Thursday, December 3

09.30–11.00	Short Oral Session 2	Room Szenario
09.32 / SO-17 Clinical Nephrology	Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Secondary Prevention of Kidney Stones: a Randomized, Double-blind, Crossover Trial (INDAPACHLOR Trial)	* Matteo Bargagli, Bern
09.37 / SO-12 Clinical Nephrology	GLP-1 Receptor Agonists Are Associated With Reduced Tolvaptan-Induced Polyuria in Autosomal Dominant Polycystic Kidney Disease	* Matteo Bargagli, Bern
09.42 / SO-09 Clinical Nephrology	Development of the urine solubility index (USI): an AI-assisted composite score for urinary stone risk stratification and monitoring — study protocolNephropathy	Jan Brügger, Horgen
09.47 / SO-04 Clinical Nephrology	Anti-nephrin autoantibodies superimposed on a collagen type IV disease phenotype: dual nephropathy and the rituximab maintenance dilemma	Jan Brügger, Horgen
09.52 / SO-11 Clinical Nephrology	Failure to thrive and Hyponatremia in Infancy: Contrasting 2 rare salt-wasting tubulopathies	Julien Caccia, Bern
09.57 / SO-22 Clinical Nephrology	Model-based meta-analysis to inform chronic kidney disease drug development	* Klervi Golhen
10.02 / SO-36 Clinical Nephrology	What do fish scales have to do with end stage kidney disease and colitis?	Catarina Mata, Lachen
10.07 / SO-34 Clinical Nephrology	Urinary Dickkopf-3 as a Potential Biomarker for Long-Term Renal Stability	* Androniki Papachristou, Basel
10.12 / SO-26 Clinical Nephrology	Phosphate Metabolism and Blood Pressure in the General Population: Modulation by Arterial Stiffness or Phosphate effect on Blood Pressure is modulated by arterial stiffness: a swiss general population-based study	* Théodore Pasquier, Genève
10.17 / SO-29 Clinical Nephrology	Sparsentan as Rescue Therapy for Treatment Refractrory PLA2R-negative Membranous Glomerulonephritis with ACE Inhibitor Intolerance	Martina Pechula Thut, Zollikerberg

* = YSN submission

Thursday, December 3

10.23/ SO-24 Clinical Nephrology	Oral Potassium Supplementation and Clinical Outcomes in Patients with Cardiorenal Syndrome: A Retrospective Cohort Study	Elena Rho, Zürich
10.28/SO-20 Clinical Nephrology	Long-term effects of palopegteriparatide on bmd and tbs in adults with chronic hypoparathyroidism: pooled results from the path forward and pathway trials	Karin Senn
10.33/ SO-25 Clinical Nephrology	Pegcetacoplan for 76 weeks maintains proteinuria reduction and eGFR stabilization for adolescent patients: VALIANT + VALE subgroup analysis.	Tobias Vogler, Zürich
10.38/ SO-33 Clinical Nephrology	Upfront Combination Therapy With Nefecon and Sparsentan in IgA Nephropathy: Early Real-World Experience	Stephanie Zappi, Aarau
10.43/ SO-28 Clinical Nephrology	Reversible IL-6-Responsive Gd-IgA1+ B Cells in Adalimumab-Associated Secondary IgA Nephropathy	Katerina Zachova, Olomouc (CZE)
10.48/SO-15 Basic Science	Impact of plasma-derived exosomes on B-cell activation and differentiation towards galactose-deficient IgA1 production in IgA nephropathy	Alica Cutkova, Olomouc (CZE)
10.53/SO-08 Basic Science	Deep visual proteomics reveals distinct proximal tubular and glomerular injury programs in experimental diabetic kidney disease	* Xiang Zheng, Aarhus (DEN)
10.58/ SO-23 Basic Science	Nearly 20 years on peritoneal dialysis: potential factors associated with long-term technique survival — a clinical case	Baiba Adamaite
11.00–11.30	Coffee break	Networking Area
11.30–12.15	Vadadustat - Clinical Experiences Current situation in Switzerland **PD Dr. Harald Seeger, Baden** The case for HIF-PHI use in dialysis patients **Prof. Philip Kalra, Salford (UK)** Patient case **Dr. Andreas Schleich, Zürich** Chair: PD Dr. Harald Seeger, Baden	Room Aare **Parallel Symposium by Salmon Pharma GmbH**

* = YSN submission

Thursday, December 3

11.30–12.15	The 2026 ESC–ERA Guidelines: Strengthening Collaboration Between Cardiology and Nephrology **Prof. Sophie de Seigneux, Genève** **Dr. Michele Vittorio Martinelli, Bern** Chair: Prof. Menno Pruijm, Lausanne	Room Szenario **Parallel Symposium by Boehringer Ingelheim (Schweiz) GmbH**
12.15–13.00	**State of the Art Lecture 2:** Normothermic regional perfusion. Technic, limitations, outcome and ethics - the experts answer a general nephrologist **PD Dr. Raphaël Giraud, Genève** **Dr. Marc Scheen, Genève** **Prof. Fabien Stucker, Neuchâtel**	Room Aare
12.15–13.00	2 experts, 2 perspectives, 1 goal ; IgAN in focus **Prof. Dr. Jörg Latus, Stuttgart (GER)** **Dr. Matthieu Halfon, Fribourg**	Room Szenario **Parallel Symposium by CSL Vifor**
12.15–13.00	**SRRQAP - Swiss Dialysis Registry and Swiss Kidney Biopsy Registry**	**Room Aare 2**
13.00–13.45	Lunch break	Networking Area
13.45–14.30	**State of the Art Lecture 3:** Conservative kidney management (CKM) and kidney supportive care (KSC) – essential components of a modern kidney service **Dr. Barnaby Hole, Bristol (UK)** **Dr. Sara Davison, Edmonton (CAN)**	Room Aare
13.45–14.30	Time is Nephron - Seizing the Window of Opportunity in IgA Nephropathy **Prof. Dr. Jörg Latus, Stuttgart (GER)** Chair: PD Dr. Harald Seeger, Baden	Room Szenario **Parallel Symposium by Spirig HealthCare AG**

Thursday, December 3

14.30–15.15	**Young Swiss Nephrology Award**	**Room Aare**
14.37/ YSN-04	Tracking proteinuria-induced tubular injury by longitudinal intravital imaging	* Anna Faivre, Genève
14.46/ YSN-03	Perioperative Fetuin-A dynamics as a potential patient-specific biomarker of acute kidney injury after cardiovascular surgery: First findings from the PEAK study	* Nathalie Hammer, Genève
14.56/ YSN-01	Diagnostic algorithm based on urinary CXCL10 for detection of rejection and infection at one-year posttransplant	* Alain Häseli, Basel
15.06/ YSN-02	Impact of Using Different eGFR Equations on the Prevalence of Chronic Kidney Disease in the General Swiss Population (SSS2-CKD Prevalence Study)	* Pierre-Antonin Rigon, Lausanne
14.30–15.15	ADVANCE-CKD – Rethinking Hypertension and CKD Trials: The Clinical Power of Surrogates Aldosterone Unmasked: The Hidden Driver of Hypertension and CKD **Prof. Dr. Hiddo Lambers Heerspink, Groningen (NED)** Unleashing the Potential of Surrogates - From Slope to Clinical Impact **Prof. Dr. Jörg Latus, Stuttgart (GER)** Chair: Prof. Dr. Grégoire Wuerzner, Lausanne	Room Szenario **Parallel Symposium by AstraZeneca AG**
15.15–15.45	Coffee break	Networking Area
15.45–17.40	**Long Oral Session 1**	**Room Aare**
15.47/ LO-10 Clinical Nephrology	Lessons learnt from a patient whose dialysis treatment could be stopped due to complement therapy	Jan Brügger, Horgen
15.57/ LO-02 Clinical Nephrology	Anti-Nephrin Antibody Positive Minimal Change Disease as a Manifestation of Graft-versus-Host Disease Following Stem Cell Transplantation – A Minimal Change?	* Mateja Kraljevic, Basel
16.07/ LO-12 Clinical Nephrology	Mechanical prosthetic valve endocarditis caused by Mycoplasma pneumoniae in a immunocompromised patient with systemic lupus erythematosus	* Stefan Achermann, Bern

* = YSN submission

Thursday, December 3

16.17 / LO-05 Clinical Nephrology	Clinical and histological responses to iptacopan in IgA-mediated glomerular disease: a real-world cohort with paired kidney biopsies	Stephanie Damm, Zürich
16.27 / LO-06 Clinical Nephrology	Discovery of anti-Formin-like Protein 1 autoantibodies in lupus nephritis patients and their clinical significance	* Filippo Donati, Genève
16.37 / LO-04 Clinical Nephrology	Biopsy-proven renal fibrosis is associated with left ventricular mass on cardio-renal MRI in chronic kidney disease	* Aurélie Huber, Genève
16.47 / LO-18 Clinical Nephrology	Renal denervation in dialysis patients with resistant hypertension: a promising treatment option	Katrin König, Liestal
16.57 / LO-22 Clinical Nephrology	When fasting turns harmful: severe hypokalaemia and rhabdomyolysis due to liquorice ingestion during Ramadan	* Olivier Linder, Bern
17.07 / LO-15 Clinical Nephrology	Postpartum recovery of renal parameters after preeclampsia in women without preexisting maternal conditions: a literature review	* Chiara Maiocchi, Bern
17.17 / LO-14 RRT	Patient-reported experiences of hand massage for CKD-associated pruritus during hemodialysis.	Michael Cordey, Lausanne
17.27 / LO-08 RRT	Hemodialysis Anticoagulation with Apixaban Following Heparin-Induced Thrombocytopenia: A Case Report	* Noemi Galliker, Burgdorf
15.45–17.40	**Long Oral Session 2**	**Room Szenario**
15.47 / LO-03 Basic Science	Bicarbonate supplementation reshapes the renal and systemic immune environment in a rat model of chronic kidney disease	* Hannah Auwerx, Zürich
15.57 / LO-11 Basic Science	Mapping tubular injury and repair states across single-cell transcriptomics and imaging mass cytometry	* Nathalie Merkel, Basel
16.07 / LO-20 Basic Science	Single-nucleus analysis reveals renal STAT1/CEBPB signaling as a modifiable relay of proinflammatory FGF23 effects in diabetic kidney disease	Matthias Moor, Bern

* = YSN submission

Thursday, December 3

16.17/ LO-01 Basic Science	An integrated single-nucleus and spatial atlas resolves compartment-specific endothelial states and glomerular niche remodeling in human kidney disease	Anna Rinaldi, Basel
16.27/ LO-19 Basic Science	Sex-dependent macrophage states and tubular repair after renal ischemia-reperfusion injury.	* Louis Stavart, Lausanne
16.37/ LO-07 Basic Science	ERMP1 safeguards metabolic integrity and limits acute ischemic injury in the kidney	* Basel Yousef, Genève
16.47/ LO-21 Transplantation	The impact of recipient age on the incidence of rejection and infection after kidney transplantation	* Matthias Diebold, Basel
16.57/ LO-09 Transplantation	Impact Of Blood Transfusions After Renal Transplantation On Clinical Outcomes And Broadness Of Sensitization	* Stella Gerber, Basel
17.07/ LO-16 Transplantation	Proteomic Profiling of Recurrent endocapillary IgA Nephropathy in Kidney Allografts Reveals a complement-dominated signature	Matthieu Halfon, Fribourg
17.17/ LO-17 Transplantation	PTLD CART-cell therapy in a kidney transplant recipient	* Mathias Stevanin, Lausanne
17.27/ LO-13 Transplantation	Molecular Consequences of Conversion from Calcineurin Inhibitor to Belatacept in Kidney Allografts	* Lukas Weidmann, Zürich
17.45–18.30	**Elevator Pitch Phase 1: all authors**	**Room Aare**
17.47/ EP-12	Simultaneous appearance of IgA nephropathy and tubulointerstitial nephritis and uveitis (TINU) syndrome: a case report	Jan Brügger, Horgen
17.48/ EP-14	What does it even mean today? - The diagnosis of the syndrome of inappropriate antidiuresis (SIAD) in a contemporary, real-world cohort.	Florian Buchkremer, Luzern
17.49/ EP-06	Novel potassium binders for enabling mineralocorticoid receptor antagonist therapy in adults with chronic kidney disease and eGFR below 45 mL/min/1.73 m²: a systematic review and structured quantitative synthesis	* Stephanie Bull-Larsen, Zürich

* = YSN submission

Thursday, December 3

17.50 / EP-15	When BCG Goes Beyond the Bladder: Suspected Disseminated BCG Infection With Severe AKI	Rolf Dieterich, Bern
17.51 / EP-05	Not All Hemolysis Is TMA: A Hidden Sickle Cell Disease Presenting with Severe AKI	Rolf Dieterich, Bern
17.52 / EP-09	Rare types of kidney stones: a case of a 1-methyluric acid kidney stone nephropathy	* Estel-Anaïs Hubaud, Lausanne
17.53 / EP-16	When typical infection-associated glomerulonephritis unmasks C3 glomerulonephritis: Targeting the alternative complement pathway with iptacopan – a case report	* Mateja Kraljevic, Basel
17.54 / EP-10	Resilience in patients with Fabry Disease and its association with disease course, psychosocial factors and quality of life: a multicentre cross-sectional study	Albina Nowak, Zürich
17.55 / EP-03	Denosumab-associated osteomalacia in a patient undergoing hemodialysis	* Alexander Orth, Bern
17.56 / EP-11	Secondary oxalate nephropathy in a kidney allograft revealing previously unrecognised enteric hyperoxaluria	* Thomas Reich Bern
17.57 / EP-08	Off-label Tolvaptan for persistent marked hyperoxaluria after kidney transplantation in primary hyperoxaluria type 2	* Thomas Reich Bern
17.58 / EP-01	An 82-Year-Old Woman with Glomerulonephritis and Acute Kidney Injury: the Therapeutic Dilemma	Heidi Sarrasin, Sion
17.59 / EP-13	Total versus Ionized Magnesium in Chronic Kidney Disease and Dialysis	Simeon Schietzel, Bern
18.00 / EP-04	Long-term renal effects of palopegteriparatide for adults with hypoparathyroidism: pooled final data from the path forward and pathway trials	Karin Senn
18.01 / EP-02	Beyond thrombocytopenia: an atypical biopsy-proven gemcitabine-induced thrombotic microangiopathy with cellular crescents	* Charlotte Storione, Moutier
18.02 / EP-07	Obinutuzumab in multidrug-resistant FSGS: a single-centre case series	Tabea Vogel, Chur

* = YSN submission

Thursday, December 3

followed by	**Presentation rating by the audience**	
followed by	**Phase 2:** **selected long presentations**	
17.45–18.30	IgAN: A Complement(ary) Perspective **Prof. Dr. Jürgen Floege, Aachen (GER)** **Dr. Gabriella Guzzo, Sion**	Room Szenario **Parallel Symposium by Alexion Pharma GmbH**
starting at 18.30	**Aperitif**	**Forum Ost Kursaal Bern**
starting at 19.15	**Networking Dinner and Awards Ceremony**	**Kursaal Arena**